Condition

Glaucoma; Drugs

ClinicalTrials.gov condition label

Clinical trials9

Recruiting0

Common interventions17

Lead sponsors shown9

Clinical trials

9 shown

The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma PatientsNCT04007276 · 2026-11-10

NOT_YET_RECRUITING

How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?NCT06369077 · 2024-04-22

Ocular Surface Disease and IOP Monitoring With Travoprost Without ConservativesNCT05319470 · 2022-03-15

INTEGRAL Study: A Longitudinal Study of Surgeries and Lasers in Glaucoma: Long-term Results and Success Predictors Analysed From a Large-scale Retrospective and Prospective Glaucoma RegisterNCT04381611 · 2019-01-15

ENROLLING_BY_INVITATION

Efficacy of Tafluprost as an Adjunct to Medical Therapy for Residual Glaucoma After TrabeculectomyNCT03595865 · 2018-08-01

CATS Tonometer IOP Reduction Latanoprost Verses TimololNCT04178863 · 2018-07-01

Efficacy and Necessity of Time Interval Between Instillation of Two Glaucoma Eye DropsNCT03220490 · 2017-11-01

Evaluation of Adherence to Clinical Treatment of GlaucomaNCT03338088 · 2017-09-01

Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography StudyNCT03323164 · 2017-07-10

Common interventions

5 minute interval between regular glaucoma drops - Long termBEHAVIORAL1 Brimonidine TartrateDRUG1 brimonidine tartrate ophthalmic solution 0.025%DRUG1 CATS TonometerDEVICE1 Conjuctival HyperemiaDIAGNOSTIC_TEST1 dorzolamide/timololDRUG1 Intraocular pressure (IOP)DIAGNOSTIC_TEST1 IOP reduction of Brimonidine and Timolol no time intervalDRUG1 IOP reduction of Brimonidine and Timolol with time intervalDRUG1 LatanoprostDRUG1 no interval between regular glaucoma drops - Long termBEHAVIORAL1 Schirmer TestDIAGNOSTIC_TEST1 sterile balanced saline solutionOTHER1 tafluprostinDRUG1 Tear Break-up Time (TBUT)DIAGNOSTIC_TEST1 Timolol MaleateDRUG1 Visual Fields and OCT RNFLDIAGNOSTIC_TEST1

Leading sponsors

CT Glaucoma Associates1 Democritus University of Thrace1 Dr. Kaweh Mansouri1 Instituto de Olhos de Goiania1 Intuor Technologies, Inc.1 Sheba Medical Center1 Tulane University1 wangdabo1 Wills Eye1

Trial status mix

UNKNOWN4

COMPLETED2

ENROLLING_BY_INVITATION1

NOT_YET_RECRUITING1

TERMINATED1

Phase mix

PHASE44

NA2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.